Connection

Michael Hallek to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Drug Resistance, Neoplasm.
Michael Hallek
Connection Strength
0.247
Drug Resistance, Neoplasm
  1. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018 02 20; 9(1):727.
    View in: PubMed
    Score: 0.135
  2. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
    View in: PubMed
    Score: 0.035
  3. Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Br J Haematol. 2017 09; 178(6):949-953.
    View in: PubMed
    Score: 0.032
  4. Emerging therapies for refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Feb; 56(2):285-92.
    View in: PubMed
    Score: 0.026
  5. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.